Home › Compare › SERNF vs ABBV
SERNF yields 2.29% · ABBV yields 3.06%● Live data
📍 SERNF pulled ahead of the other in Year 7
Combined, SERNF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SERNF + ABBV for your $10,000?
Seiren Co.,Ltd. plans, manufactures, and markets textile and chemical products, industrial machines, and electronic parts in Japan and internationally. The company operates through Automotive Upholstery Materials, Electronics Materials, High Fashion Materials, Environmental & Life Materials, and Medical Materials segments. The Automotive Upholstery Materials segment offers car seat cover, instrument panel (decorative), and airbag materials. The Electronics Materials segment provides electrically conductive and high-performance wiping cloth materials, high-strength yarns, and precision devices. The Environmental & Life Materials segment offers house exterior wall covering moisture-permeable waterproof sheet materials, office interior materials, civil engineering materials, and nursing care-related materials. The High Fashion Materials segment offers fashion clothing, sports outdoor clothing, and inner clothing materials. The Medical Materials segment provides cosmetics/pharmaceutical related, medical care, and nursing care materials. It also offers digital production systems; and civil engineering, construction, interior, and industrial materials The company was formerly known as Fukui Seiren Kako Co., Ltd. and changed its name to Seiren Co.,Ltd. in 1973. Seiren Co.,Ltd. was founded in 1889 and is headquartered in Tokyo, Japan.
Full SERNF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.